Both Silodosin 4 mg and Dapoxetine 60 mg significantly improved IELT and sexual function scores in primary PE patients. However, Silodosin exhibited a more favorable tolerability profile with fewer side effects, making it a safer, clinically effective alternative.

Dapoxetine 60 mg, the initial FDA-approved on-demand treatment for PE, which is a selective serotonin reuptake inhibitor (SSRI) . However, Silodosin 4 mg, an α1-adrenoceptor antagonist, has emerged as a promising alternative, particularly for patients dissatisfied with Dapoxetine . This investigation is designed to evaluate the efficacy and tolerability of Silodosin 4mg and Dapoxetine 60mg in the treatment of primary premature ejaculation.

Inclusion Criteria:

• Heterosexual male
• Sexually active
• Aged 25 to 65 years old.
• Primary premature ejaculation (IELT < 1 minute)
• They had experienced PE for a minimum of 6 months

Exclusion Criteria:

• Patients with a history of diabetes or
• Uncontrolled hypertension (systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg) was precluded from the study.
• Anatomic abnormalities of the penis or genital region,
• Erectile dysfunction,
• Chronic prostatitis,
• Psychological disorder
• Patients on anti-psychotic drugs.

male patients in heterosexual relation

it will be shared upon request